Edaravone

Active ingredient: Edaravone

In short: Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Forms & strengthsEdaravone injection is supplied for intravenous infusion in a single-dose polypropylene bag containing 30 mg of edaravone in 100 mL of clear, colorless aqueous solution.
LabelPiramal Critical Care Inc.
Label updatedNov 17, 2025

What is Edaravone used for?

Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Edaravone dosage

The recommended dosage of edaravone injection: an intravenous infusion of 60 mg administered over a 60-minute period.

Administer Edaravone injection according to the following schedule:

An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug-free period

Subsequent treatment cycles with daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods.

Edaravone injection is for intravenous infusion only.

Preparation

Do not use if the oxygen indicator has turned blue or purple before opening the package

.Once the overwrap package is opened, use within 24 hours

.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard unused portion.

Administration

Administer a 60 mg dose of edaravone injection as two consecutive 30 mg intravenous infusion bag over a total of 60 minutes (infusion rate approximately 1 mg per minute [3.33 mL per minute]).

Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction

.

Other medications should not be injected into the infusion bag or mixed with edaravone injection.

Patients treated with 60 mg of edaravone injection intravenous infusion may be switched to 105 mg (5 mL) Radicava ORS using the same dosing frequency.

How to take Edaravone — instructions & advice from the label

Advise the patients to read the FDA-approved patient labeling (Patient Information).

Hypersensitivity Reactions

Advise patients to seek immediate medical care if they experience signs or symptoms of a hypersensitivity reaction

.

Sulfite Allergic Reactions

Advise patients about potential for sulfite sensitivity. Inform patients that edaravone injection contains sodium bisulfite, which may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, and to seek immediate medical care if they experience these signs or symptoms

.

Pregnancy and Breastfeeding

Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during edaravone injection therapy

.

Advise patients to notify their healthcare provider if they intend to breastfeed or are breastfeeding an infant

.

Manufactured for:

Piramal Crtical Care, Inc.

Bethlehem, PA 18017, USA

Issued: 09/2023

PATIENT INFORMATION

Edaravone Injection (e-dar-a-vone)

for intravenous use

What is Edaravone Injection?

Edaravone injection is a prescription medicine used to treat people with amyotrophic lateral sclerosis (ALS). …

Warnings & precautions

Do not take this medicine if: Edaravone injection is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in this product. Hypersensitivity reactions and anaphylactic reactions have occurred

.

Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported in spontaneous postmarketing reports with edaravone injection.

Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue edaravone injection, treat per standard of care, and monitor until the condition resolves

.

Edaravone injection contains sodium bisulfite, a sulfite that may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown. Sulfite sensitivity occurs more frequently in asthmatic than non-asthmatic people.

Edaravone side effects

The following serious adverse reactions are described elsewhere in the labeling:

• Hypersensitivity Reactions

• Sulfite Allergic Reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In randomized, placebo-controlled trials, 184 patients with ALS were administered edaravone injection 60 mg in treatment cycles for 6 months. The population consisted of Japanese patients who had a median age of 60 years (range 29 to ­75) and were 59% male. Most (93%) of these patients were living independently at the time of screening.

Most Common Adverse Reactions Observed During Clinical Studies

Table 2 lists the adverse reactions that occurred in ≥ 2% of patients in the edaravone injection-treated group and that occurred at least 2% more frequently than in the placebo-treated group in randomized placebo-controlled ALS trials. The most common adverse reactions that occurred in ≥ 10% of edaravone injection-treated patients were contusion, gait disturbance, and headache. …

About this medicine

The active ingredient in edaravone injection is edaravone, which is a member of the substituted 2-pyrazolin-5-one class. The chemical name of edaravone is [3-methyl-1-phenyl-2-pyrazolin-5-one]. The molecular formula is C

10H

10N

2O and the molecular weight is 174.20.

The chemical structure is:

Edaravone is a white crystalline powder with a melting point of 129.7°C. It is freely soluble in acetic acid, methanol, or ethanol and slightly soluble in water or diethyl ether.

Edaravone injection is a clear, colorless liquid provided as a sterile solution.

Edaravone injection is supplied for intravenous infusion in a polypropylene bag containing 30 mg edaravone in 100 mL isotonic, sterile, aqueous solution, which is further overwrapped with clear pouch. The overwrapped package also contains an oxygen absorber and oxygen indicator to minimize oxidation. Clear pouch is further overwrapped in PET pouch. Each bag contains the following inactive ingredients: L-cysteine hydrochloride hydrate (10 mg), sodium bisulfite (20 mg). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 19862ae9-d6e1-70e6-e063-6394a90ae749. Read the full official label on DailyMed.